Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Operating Income (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Operating Income data on record, last reported at -$10.6 million in Q3 2025.

  • For Q3 2025, Operating Income fell 45.72% year-over-year to -$10.6 million; the TTM value through Sep 2025 reached -$38.0 million, down 51.47%, while the annual FY2023 figure was -$23.4 million, 28.12% up from the prior year.
  • Operating Income reached -$10.6 million in Q3 2025 per CRVS's latest filing, down from -$10.3 million in the prior quarter.
  • Across five years, Operating Income topped out at -$5.6 million in Q3 2023 and bottomed at -$12.5 million in Q3 2022.
  • Average Operating Income over 4 years is -$7.6 million, with a median of -$6.8 million recorded in 2022.
  • Peak YoY movement for Operating Income: soared 55.42% in 2023, then tumbled 72.87% in 2025.
  • A 4-year view of Operating Income shows it stood at -$5.7 million in 2022, then grew by 0.26% to -$5.7 million in 2023, then fell by 28.38% to -$7.3 million in 2024, then plummeted by 45.72% to -$10.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$10.6 million in Q3 2025, -$10.3 million in Q2 2025, and -$9.9 million in Q1 2025.